LumiThera expands Valeda research into diabetic retinopathy

LumiThera is expanding research of its photobiomodulation platform, the Valeda light delivery system, with new studies evaluating its use in patients with diabetic retinopathy, the company announced in a press release.
The Valeda system has received a CE mark in Europe for the treatment of ocular diseases including dry age-related macular degeneration. The new studies in diabetic retinopathy will take place with the University of Wisconsin-Milwaukee.
“Recent research in our labs in both preclinical and clinical areas have indicated potential in treating diabetic edema with

Full Story →